Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer.

Aimée R. Kreimer, Mattias Johansson, Tim Waterboer, Rudolf Kaaks, Jenny Chang-Claude, Dagmar Drogen, Anne Tjønneland, Kim Overvad, J. Ramón Quirós, Carlos A. González, Maria José Sánchez, Nerea Larrañaga, Carmen Navarro, Aurelio Barricarte, Ruth C. Travis, Kay Tee Khaw, Nick Wareham, Antonia Trichopoulou, Pagona Lagiou, Dimitrios TrichopoulosPetra H M Peeters, Salvatore Panico, Giovanna Masala, Sara Grioni, Rosario Tumino, Paolo Vineis, H. Bas Bueno-de-Mesquita, Göran Laurell, Göran Hallmans, Jonas Manjer, Johanna Ekström, Guri Skeie, Eiliv Lund, Elisabete Weiderpass, Pietro Ferrari, Graham Byrnes, Isabelle Romieu, Elio Riboli, Allan Hildesheim, Heiner Boeing, Michael Pawlita, Paul Brennan

Research output: Contribution to journalArticle

167 Citations (Scopus)

Abstract

Human papillomavirus type 16 (HPV16) infection is causing an increasing number of oropharyngeal cancers in the United States and Europe. The aim of our study was to investigate whether HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic sera. We identified 638 participants with incident head and neck cancers (patients; 180 oral cancers, 135 oropharynx cancers, and 247 hypopharynx/larynx cancers) and 300 patients with esophageal cancers as well as 1,599 comparable controls from within the European Prospective Investigation Into Cancer and Nutrition cohort. Prediagnostic plasma samples from patients (collected, on average, 6 years before diagnosis) and control participants were analyzed for antibodies against multiple proteins of HPV16 as well as HPV6, HPV11, HPV18, HPV31, HPV33, HPV45, and HPV52. Odds ratios (ORs) of cancer and 95% CIs were calculated, adjusting for potential confounders. All-cause mortality was evaluated among patients using Cox proportional hazards regression. HPV16 E6 seropositivity was present in prediagnostic samples for 34.8% of patients with oropharyngeal cancer and 0.6% of controls (OR, 274; 95% CI, 110 to 681) but was not associated with other cancer sites. The increased risk of oropharyngeal cancer among HPV16 E6 seropositive participants was independent of time between blood collection and diagnosis and was observed more than 10 years before diagnosis. The all-cause mortality ratio among patients with oropharyngeal cancer was 0.30 (95% CI, 0.13 to 0.67), for patients who were HPV16 E6 seropositive compared with seronegative. HPV16 E6 seropositivity was present more than 10 years before diagnosis of oropharyngeal cancers.

Original languageEnglish
Pages (from-to)2708-2715
Number of pages8
JournalJournal of Clinical Oncology
Volume31
Issue number21
Publication statusPublished - Jul 20 2013

Fingerprint

Oropharyngeal Neoplasms
Head and Neck Neoplasms
Human papillomavirus 16
Antibodies
Odds Ratio
Hypopharynx
Neoplasms
Laryngeal Neoplasms
Papillomavirus Infections
Mortality
Mouth Neoplasms
Esophageal Neoplasms
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kreimer, A. R., Johansson, M., Waterboer, T., Kaaks, R., Chang-Claude, J., Drogen, D., ... Brennan, P. (2013). Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. Journal of Clinical Oncology, 31(21), 2708-2715.

Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. / Kreimer, Aimée R.; Johansson, Mattias; Waterboer, Tim; Kaaks, Rudolf; Chang-Claude, Jenny; Drogen, Dagmar; Tjønneland, Anne; Overvad, Kim; Quirós, J. Ramón; González, Carlos A.; Sánchez, Maria José; Larrañaga, Nerea; Navarro, Carmen; Barricarte, Aurelio; Travis, Ruth C.; Khaw, Kay Tee; Wareham, Nick; Trichopoulou, Antonia; Lagiou, Pagona; Trichopoulos, Dimitrios; Peeters, Petra H M; Panico, Salvatore; Masala, Giovanna; Grioni, Sara; Tumino, Rosario; Vineis, Paolo; Bueno-de-Mesquita, H. Bas; Laurell, Göran; Hallmans, Göran; Manjer, Jonas; Ekström, Johanna; Skeie, Guri; Lund, Eiliv; Weiderpass, Elisabete; Ferrari, Pietro; Byrnes, Graham; Romieu, Isabelle; Riboli, Elio; Hildesheim, Allan; Boeing, Heiner; Pawlita, Michael; Brennan, Paul.

In: Journal of Clinical Oncology, Vol. 31, No. 21, 20.07.2013, p. 2708-2715.

Research output: Contribution to journalArticle

Kreimer, AR, Johansson, M, Waterboer, T, Kaaks, R, Chang-Claude, J, Drogen, D, Tjønneland, A, Overvad, K, Quirós, JR, González, CA, Sánchez, MJ, Larrañaga, N, Navarro, C, Barricarte, A, Travis, RC, Khaw, KT, Wareham, N, Trichopoulou, A, Lagiou, P, Trichopoulos, D, Peeters, PHM, Panico, S, Masala, G, Grioni, S, Tumino, R, Vineis, P, Bueno-de-Mesquita, HB, Laurell, G, Hallmans, G, Manjer, J, Ekström, J, Skeie, G, Lund, E, Weiderpass, E, Ferrari, P, Byrnes, G, Romieu, I, Riboli, E, Hildesheim, A, Boeing, H, Pawlita, M & Brennan, P 2013, 'Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer.', Journal of Clinical Oncology, vol. 31, no. 21, pp. 2708-2715.
Kreimer AR, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. Journal of Clinical Oncology. 2013 Jul 20;31(21):2708-2715.
Kreimer, Aimée R. ; Johansson, Mattias ; Waterboer, Tim ; Kaaks, Rudolf ; Chang-Claude, Jenny ; Drogen, Dagmar ; Tjønneland, Anne ; Overvad, Kim ; Quirós, J. Ramón ; González, Carlos A. ; Sánchez, Maria José ; Larrañaga, Nerea ; Navarro, Carmen ; Barricarte, Aurelio ; Travis, Ruth C. ; Khaw, Kay Tee ; Wareham, Nick ; Trichopoulou, Antonia ; Lagiou, Pagona ; Trichopoulos, Dimitrios ; Peeters, Petra H M ; Panico, Salvatore ; Masala, Giovanna ; Grioni, Sara ; Tumino, Rosario ; Vineis, Paolo ; Bueno-de-Mesquita, H. Bas ; Laurell, Göran ; Hallmans, Göran ; Manjer, Jonas ; Ekström, Johanna ; Skeie, Guri ; Lund, Eiliv ; Weiderpass, Elisabete ; Ferrari, Pietro ; Byrnes, Graham ; Romieu, Isabelle ; Riboli, Elio ; Hildesheim, Allan ; Boeing, Heiner ; Pawlita, Michael ; Brennan, Paul. / Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 21. pp. 2708-2715.
@article{b68fc603ad2b455a83e3081dc1ecc592,
title = "Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer.",
abstract = "Human papillomavirus type 16 (HPV16) infection is causing an increasing number of oropharyngeal cancers in the United States and Europe. The aim of our study was to investigate whether HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic sera. We identified 638 participants with incident head and neck cancers (patients; 180 oral cancers, 135 oropharynx cancers, and 247 hypopharynx/larynx cancers) and 300 patients with esophageal cancers as well as 1,599 comparable controls from within the European Prospective Investigation Into Cancer and Nutrition cohort. Prediagnostic plasma samples from patients (collected, on average, 6 years before diagnosis) and control participants were analyzed for antibodies against multiple proteins of HPV16 as well as HPV6, HPV11, HPV18, HPV31, HPV33, HPV45, and HPV52. Odds ratios (ORs) of cancer and 95{\%} CIs were calculated, adjusting for potential confounders. All-cause mortality was evaluated among patients using Cox proportional hazards regression. HPV16 E6 seropositivity was present in prediagnostic samples for 34.8{\%} of patients with oropharyngeal cancer and 0.6{\%} of controls (OR, 274; 95{\%} CI, 110 to 681) but was not associated with other cancer sites. The increased risk of oropharyngeal cancer among HPV16 E6 seropositive participants was independent of time between blood collection and diagnosis and was observed more than 10 years before diagnosis. The all-cause mortality ratio among patients with oropharyngeal cancer was 0.30 (95{\%} CI, 0.13 to 0.67), for patients who were HPV16 E6 seropositive compared with seronegative. HPV16 E6 seropositivity was present more than 10 years before diagnosis of oropharyngeal cancers.",
author = "Kreimer, {Aim{\'e}e R.} and Mattias Johansson and Tim Waterboer and Rudolf Kaaks and Jenny Chang-Claude and Dagmar Drogen and Anne Tj{\o}nneland and Kim Overvad and Quir{\'o}s, {J. Ram{\'o}n} and Gonz{\'a}lez, {Carlos A.} and S{\'a}nchez, {Maria Jos{\'e}} and Nerea Larra{\~n}aga and Carmen Navarro and Aurelio Barricarte and Travis, {Ruth C.} and Khaw, {Kay Tee} and Nick Wareham and Antonia Trichopoulou and Pagona Lagiou and Dimitrios Trichopoulos and Peeters, {Petra H M} and Salvatore Panico and Giovanna Masala and Sara Grioni and Rosario Tumino and Paolo Vineis and Bueno-de-Mesquita, {H. Bas} and G{\"o}ran Laurell and G{\"o}ran Hallmans and Jonas Manjer and Johanna Ekstr{\"o}m and Guri Skeie and Eiliv Lund and Elisabete Weiderpass and Pietro Ferrari and Graham Byrnes and Isabelle Romieu and Elio Riboli and Allan Hildesheim and Heiner Boeing and Michael Pawlita and Paul Brennan",
year = "2013",
month = "7",
day = "20",
language = "English",
volume = "31",
pages = "2708--2715",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "21",

}

TY - JOUR

T1 - Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer.

AU - Kreimer, Aimée R.

AU - Johansson, Mattias

AU - Waterboer, Tim

AU - Kaaks, Rudolf

AU - Chang-Claude, Jenny

AU - Drogen, Dagmar

AU - Tjønneland, Anne

AU - Overvad, Kim

AU - Quirós, J. Ramón

AU - González, Carlos A.

AU - Sánchez, Maria José

AU - Larrañaga, Nerea

AU - Navarro, Carmen

AU - Barricarte, Aurelio

AU - Travis, Ruth C.

AU - Khaw, Kay Tee

AU - Wareham, Nick

AU - Trichopoulou, Antonia

AU - Lagiou, Pagona

AU - Trichopoulos, Dimitrios

AU - Peeters, Petra H M

AU - Panico, Salvatore

AU - Masala, Giovanna

AU - Grioni, Sara

AU - Tumino, Rosario

AU - Vineis, Paolo

AU - Bueno-de-Mesquita, H. Bas

AU - Laurell, Göran

AU - Hallmans, Göran

AU - Manjer, Jonas

AU - Ekström, Johanna

AU - Skeie, Guri

AU - Lund, Eiliv

AU - Weiderpass, Elisabete

AU - Ferrari, Pietro

AU - Byrnes, Graham

AU - Romieu, Isabelle

AU - Riboli, Elio

AU - Hildesheim, Allan

AU - Boeing, Heiner

AU - Pawlita, Michael

AU - Brennan, Paul

PY - 2013/7/20

Y1 - 2013/7/20

N2 - Human papillomavirus type 16 (HPV16) infection is causing an increasing number of oropharyngeal cancers in the United States and Europe. The aim of our study was to investigate whether HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic sera. We identified 638 participants with incident head and neck cancers (patients; 180 oral cancers, 135 oropharynx cancers, and 247 hypopharynx/larynx cancers) and 300 patients with esophageal cancers as well as 1,599 comparable controls from within the European Prospective Investigation Into Cancer and Nutrition cohort. Prediagnostic plasma samples from patients (collected, on average, 6 years before diagnosis) and control participants were analyzed for antibodies against multiple proteins of HPV16 as well as HPV6, HPV11, HPV18, HPV31, HPV33, HPV45, and HPV52. Odds ratios (ORs) of cancer and 95% CIs were calculated, adjusting for potential confounders. All-cause mortality was evaluated among patients using Cox proportional hazards regression. HPV16 E6 seropositivity was present in prediagnostic samples for 34.8% of patients with oropharyngeal cancer and 0.6% of controls (OR, 274; 95% CI, 110 to 681) but was not associated with other cancer sites. The increased risk of oropharyngeal cancer among HPV16 E6 seropositive participants was independent of time between blood collection and diagnosis and was observed more than 10 years before diagnosis. The all-cause mortality ratio among patients with oropharyngeal cancer was 0.30 (95% CI, 0.13 to 0.67), for patients who were HPV16 E6 seropositive compared with seronegative. HPV16 E6 seropositivity was present more than 10 years before diagnosis of oropharyngeal cancers.

AB - Human papillomavirus type 16 (HPV16) infection is causing an increasing number of oropharyngeal cancers in the United States and Europe. The aim of our study was to investigate whether HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic sera. We identified 638 participants with incident head and neck cancers (patients; 180 oral cancers, 135 oropharynx cancers, and 247 hypopharynx/larynx cancers) and 300 patients with esophageal cancers as well as 1,599 comparable controls from within the European Prospective Investigation Into Cancer and Nutrition cohort. Prediagnostic plasma samples from patients (collected, on average, 6 years before diagnosis) and control participants were analyzed for antibodies against multiple proteins of HPV16 as well as HPV6, HPV11, HPV18, HPV31, HPV33, HPV45, and HPV52. Odds ratios (ORs) of cancer and 95% CIs were calculated, adjusting for potential confounders. All-cause mortality was evaluated among patients using Cox proportional hazards regression. HPV16 E6 seropositivity was present in prediagnostic samples for 34.8% of patients with oropharyngeal cancer and 0.6% of controls (OR, 274; 95% CI, 110 to 681) but was not associated with other cancer sites. The increased risk of oropharyngeal cancer among HPV16 E6 seropositive participants was independent of time between blood collection and diagnosis and was observed more than 10 years before diagnosis. The all-cause mortality ratio among patients with oropharyngeal cancer was 0.30 (95% CI, 0.13 to 0.67), for patients who were HPV16 E6 seropositive compared with seronegative. HPV16 E6 seropositivity was present more than 10 years before diagnosis of oropharyngeal cancers.

UR - http://www.scopus.com/inward/record.url?scp=84883134703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883134703&partnerID=8YFLogxK

M3 - Article

C2 - 23775966

AN - SCOPUS:84883134703

VL - 31

SP - 2708

EP - 2715

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 21

ER -